Scarica l'app Stockscreener
310.71
0.04%
0.13
Dopo l'orario di chiusura:
308.80
-1.91
-0.61%
Precedente Chiudi:
$310.58
Aprire:
$303.32
Volume 24 ore:
221.42K
Relative Volume:
0.37
Capitalizzazione di mercato:
$8.65B
Reddito:
$1.77M
Utile/perdita netta:
$-123.74M
Rapporto P/E:
-33.88
EPS:
-9.17
Flusso di cassa netto:
$-95.21M
1 W Prestazione:
-7.73%
1M Prestazione:
-2.77%
6M Prestazione:
+563.20%
1 anno Prestazione:
+720.46%
Intervallo 1D:
$303.01
$316.46
Intervallo di 1 settimana:
$303.01
$342.51
Portata 52W:
$26.70
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
310.71 | 8.65B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Wells Fargo | Equal Weight |
| 2025-12-15 | Reiterato | Oppenheimer | Outperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position - MSN
Praxis Precision Medicines, Inc. $PRAX Shares Bought by Rafferty Asset Management LLC - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Shares Sold by TD Asset Management Inc - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A Look At Praxis Precision Medicines (PRAX) Valuation After Wider Full Year And Q4 Net Loss - simplywall.st
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Praxis gives 2,931 stock units to 14 new employees - Stock Titan
PRAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Praxis Eyes Blockbuster Future As Precision Neurology Pipeline Matures - Citeline News & Insights
Why (PRAX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
GSA Capital Partners LLP Trims Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Powerhouse with 76% Upside Potential - DirectorsTalk Interviews
How Investors Are Reacting To Praxis (PRAX) Wider Losses, Fresh NDAs And Multi‑Year Cash Runway - simplywall.st
Praxis Precision Medicines stock hits 52-week high at 327.0 USD - Investing.com Nigeria
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Wolfe Research - MarketBeat
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Assessing Praxis Precision Medicines (PRAX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Wolfe Research initiates Praxis stock with outperform rating - Investing.com
Wolfe Research initiates Praxis stock with outperform rating By Investing.com - Investing.com India
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
Wolfe Research Initiates Coverage of Praxis Precision Medicines (PRAX) with Outperform Recommendation - Nasdaq
Wolfe Research Initiates Coverage on Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus
A Look At Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum - Yahoo Finance
3,826 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by ProShare Advisors LLC - MarketBeat
Praxis NDAs And FDA Designations Put Focus On Valuation Upside - Yahoo! Finance Canada
Praxis Precision Medicines Maps Aggressive Path to Market - TipRanks
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - Yahoo Finance
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - The Motley Fool
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress - AOL.com
Praxis Medicines Q4 2025 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Analyst Upgrade - Defense World
PRAX Stock: Wells Fargo Raises Price Target to $305 | PRAX Stock News - GuruFocus
Praxis Precision shares rally on price target hikes: Analyst sees upside as high as 100% for stock - MSN
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Asianet Newsable
Praxis Precision Medicines stock reaches 52-week high at 337.01 USD - Investing.com
Baird Raises Price Target for PRAX to $433, Maintains Outperform Rating | PRAX Stock News - GuruFocus
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
Praxis Precision Medicines Stock Surges on FDA Momentum - TipRanks
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Truist Financial Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Wedbush Raises Price Target on Praxis Precision Medicines to $130 From $95, Keeps Underperform Rating - marketscreener.com
Truist Boosts Price Target on Praxis Precision Medicines to $700 From $500, Keeps Buy Rating - marketscreener.com
Deutsche Bank Raises Price Target on Praxis Precision Medicines to $412 From $357, Keeps Buy Rating - marketscreener.com
Wedbush Raises Price Target for PRAX to $130 Despite 'Underperfo - GuruFocus
Wedbush Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Pioneer with an 80.92% Potential Upside - DirectorsTalk Interviews
Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline Toward Commercialization with Multibillion-Dollar Market Potential - TipRanks
Earnings call transcript: Praxis Precision Q4 2025 misses EPS forecast By Investing.com - Investing.com Canada
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
2.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):